Copyright © Inderes 2011 - present. All rights reserved.

Oriola

1.20 EUR

-0.50 %

7,770 following
Corporate customer

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.50 %
+4.35 %
+5.08 %
+7.14 %
+5.82 %
+27.80 %
-32.51 %
-41.75 %
-34.76 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
222.39M EUR
Turnover
63.61K EUR
P/E (adj.) (25e)
28.61
EV/EBIT (adj.) (25e)
6.36
P/B (25e)
2.28
EV/S (25e)
0.08
Dividend yield-% (25e)
3.33 %
Coverage
Recommendation
Reduce
Target price
1.25 EUR
Updated
14.01.2026
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Latest research

Latest analysis report

Released: 14.01.2026

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25.2
2026

Annual report '25

25.3
2026

General meeting '26

29.4
2026

Interim report Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Oriola: Earnings turning positive - Evli

Oriola posted good Q3 results, with a key positive the faster recovery than we had expected recovery of profitability in the Wholesale segment. With good development across the board, earnings also turned positive. We raise our target price to EUR 1....

Oriola
Third party research

Oriola: Good development across the board - Evli

Oriola posted good figures in Q3. Net sales growth was nearly in the double-digits, while the adj. EBITDA of EUR 9.6m exceeded our EUR 9.1m expectations. Profitability was aided by faster than anticipated profitability recovery of the Wholesale-segment...

Oriola
Third party research

Oriola: Growth in place, profitability next - Evli

Oriola saw solid growth in Q2, and we anticipate a continued good growth pace in Q3. We expect the weaker profitability in the Wholesale-segment to improve gradually during the second half of the year, enabling y/y group level improvement.

Oriola
Third party research

Oriola: Profitability drivers in place - Evli

Solid growth, profitability on previous year levels Oriola posted solid growth figures in Q2, while profitability development remained modest. Net sales growth exceeded our expectations, up 12% y/y to EUR 493.9m (EUR 473.7m/496.7m Evli/cons.). The adj...

Oriola
Forum discussions
This post is primarily intended for Oriola’s communications and finance departments as a comment for improving Oriola’s financial reporting and for the Capital Markets Day. The biggest problem with Oriola’s financial reporting is that true and fair information regarding the JV company...
1/19/2026, 2:10 PM
by Aktivisti26
15
The most sensible thing would be to freeze dividends completely for at least a couple of years. It’s idiotic to pay out dividends and then beg for the money back shortly after in a share issue. Naturally, via a directed issue at a discount, just to maximize the retail investors’ ...
1/14/2026, 3:15 PM
by tj_hodl
6
I already commented briefly on those thoughts from Aktivisten back in the autumn in this post. I still completely agree (as does @Makex above) that regarding Kronans’ valuation, Aktivisten is way off track. And since Oriola needs to strengthen its balance sheet due to a low equity...
1/14/2026, 7:16 AM
by Rauli_Juva
6
Hard to say, as it’s not very attractive in its current state (zero result and a very small share of e-commerce, where the market growth is). Our valuation for Oriola’s share is 75 MEUR. In my opinion, stating this “officially” and starting the process mainly creates an acute need...
1/14/2026, 1:23 PM
by Rauli_Juva
4
Selling Kronans Apotek would not remove the value from the balance sheet… It would change the asset to cash…
1/14/2026, 1:07 PM
by Fredrik
3
Okay, that’s clear. A dividend cut in itself doesn’t affect the company’s value, but of course, if it’s due to weakening free cash flow, then it’s a different story. There are indeed risks in Oriola, such as major development projects and the book value of the joint venture. But ...
1/14/2026, 7:21 AM
by tj_hodl
3
If they end up selling Kronans, its EV must be over 460m to avoid a loss for Oriola after the latest impairment. A sale below that value would also reduce equity. The problem lies in the high EVs used when the joint venture was established (9.2.2022): The enterprise value of Oriola...
1/14/2026, 4:55 PM
by Makex
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.